Try our Advanced Search for more refined results

Biovail In Trouble With Shareholders Over Aplenzin

By Shannon Henson (October 9, 2008, 12:00 AM EDT) -- Two months after settling a securities class action for $138 million, pharmaceutical giant Biovail Corp. faces another potentially expensive shareholder suit, alleging it misled investors about documents it filed with the U.S. Food and Drug Administration to win approval of an antidepressant....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Judge Analytics

powered by Lex Machina®

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!